ZINBRYTA

This brand name is authorized in Estonia, Lithuania

Active ingredients

The drug ZINBRYTA contains one active pharmaceutical ingredient (API):

1 Daclizumab UNII CUJ2MVI71Y - DACLIZUMAB
Daclizumab beta is a humanised IgG1 monoclonal antibody that binds to CD25 (IL-2Rα), and prevents IL-2 binding to CD25, resulting in higher levels of IL-2 available for signalling through the intermediate-affinity IL-2 receptor. Key effects of this IL-2 pathway modulation potentially related to the therapeutic effects of daclizumab beta in MS include selective antagonism of activated T-cell responses, and expansion of immunoregulatory CD56^bright natural killer (NK) cells, which have been shown to selectively decrease activated T-cells. Read about Daclizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZINBRYTA Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AC01	Daclizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1725746, 1725757, 1725768, 1725779
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1080759, 1080760, 1080761, 1080762

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.